ReviewPharmacological reports : PR2026
Common features in the gut microbiota of underweight and overweight individuals and patients with Parkinson's disease - a mini-review.
Review in Pharmacological reports : PR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study explores the complex relationship between gut microbiota composition, body weight, and Parkinson’s disease (PD). Recognizing that microbiota profiles vary across Body Mass Index (BMI) categories: underweight, normal weight, and overweight, here we investigate how these differences may correlate with PD pathogenesis and the severity of the disease. The findings highlight common dysbiotic features, such as increased pro-inflammatory bacteria, observed in both PD and obesity, suggesting the involvement of shared inflammatory pathways in disease development. Conversely, all three groups: individuals with underweight, obesity, and PD exhibit reduced abundance of beneficial bacteria, which potentially impairs immune and metabolic functions, such as carbohydrate turnover and short-chain fatty acids (SCFAs) delivery. Following this analysis, we focus on and briefly discuss dietary patterns, which emerge as key modulators of gut microbiota. Plant-based and Mediterranean diets promote beneficial microbes and SCFAs production, while diets high in saturated fats and processed foods contribute to detrimental microbial shifts. Understanding these interactions underscores the importance of personalized approaches (including nutritional) targeting gut microbiota modulation as potential therapeutic avenues in PD. This integrative perspective advocates for further multidisciplinary research to elucidate causal mechanisms and develop microbiota-focused interventions aimed at delaying neurodegeneration and improving PD patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.